These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 17380842)

  • 1. The question of whether diabetes and its cardiovascular risks can be prevented: a realistic DREAM?
    Hedner T; Narkiewicz K; Oparil S; Kjeldsen SE
    Blood Press; 2006; 15(5):260-2. PubMed ID: 17380842
    [No Abstract]   [Full Text] [Related]  

  • 2. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial.
    Gerstein HC; Yusuf S; Holman R; Bosch J; Pogue J;
    Diabetologia; 2004 Sep; 47(9):1519-27. PubMed ID: 15322749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE.
    Gerstein HC
    Diabetes Metab Res Rev; 2002; 18 Suppl 3():S82-5. PubMed ID: 12324991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The DREAM of diabetes prevention].
    Ruiz J
    Rev Med Suisse; 2007 Jan; 3(94):132, 134-6. PubMed ID: 17354538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New drugs for the treatment of diabetes mellitus: part I: Thiazolidinediones and their evolving cardiovascular implications.
    McGuire DK; Inzucchi SE
    Circulation; 2008 Jan; 117(3):440-9. PubMed ID: 18212301
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes.
    ; Gerstein HC; Mohan V; Avezum A; Bergenstal RM; Chiasson JL; Garrido M; MacKinnon I; Rao PV; Zinman B; Jung H; Joldersma L; Bosch J; Yusuf S
    Diabetologia; 2011 Mar; 54(3):487-95. PubMed ID: 21116607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosiglitazone in the prevention of diabetes and cardiovascular disease: dream or reality?
    Stulc T; Ceska R
    Med Sci Monit; 2008 Apr; 14(4):RA45-7. PubMed ID: 18376358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetes prevention: still no effective drugs.
    Prescrire Int; 2007 Dec; 16(92):258. PubMed ID: 18095391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rosiglitazone.
    Simon D
    Prim Care Diabetes; 2009 May; 3(2):123-4. PubMed ID: 19482530
    [No Abstract]   [Full Text] [Related]  

  • 10. DREAM study and its impact on India.
    Mohan V
    J Assoc Physicians India; 2006 Oct; 54():765-7. PubMed ID: 17214271
    [No Abstract]   [Full Text] [Related]  

  • 11. HOPE for all people with diabetes? Heart Outcomes Prevention Evaluation.
    Marshall SM
    Diabet Med; 2000 Sep; 17 Suppl 2():9-10. PubMed ID: 11048826
    [No Abstract]   [Full Text] [Related]  

  • 12. [DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular desease].
    Scheen AJ
    Rev Med Liege; 2006 Oct; 61(10):728-32. PubMed ID: 17209507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Diabetes Prevention Program.
    Muniyappa R; El-Atat F; Aneja A; McFarlane SI
    Curr Diab Rep; 2003 Jun; 3(3):221-2. PubMed ID: 12762969
    [No Abstract]   [Full Text] [Related]  

  • 14. [Recent topics in the Japan Diabetes Outcome Intervention Trial].
    Izumi K; Kato M; Noda M
    Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):824-33. PubMed ID: 19472546
    [No Abstract]   [Full Text] [Related]  

  • 15. [Influence of diabetes incidence by ramipril and rosiglitazone: DREAM study (diabetes reduction assessment with ramipril and rosiglitazone medication)].
    Standl E; Nitschmann S
    Internist (Berl); 2007 Oct; 48(10):1173-6. PubMed ID: 17846732
    [No Abstract]   [Full Text] [Related]  

  • 16. Inhibition of the RAS and prevention of diabetes and CVD: mechanistic insights and lessons learned from clinical trials.
    McFarlane SI; Borer JS
    Curr Diab Rep; 2009 Feb; 9(1):1-3. PubMed ID: 19192416
    [No Abstract]   [Full Text] [Related]  

  • 17. [How does the PROactive Study change therapy of diabetes?].
    Erdmann E
    MMW Fortschr Med; 2005 Oct; 147(41):6. PubMed ID: 16270501
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.
    Lancet; 2000 Jan; 355(9200):253-9. PubMed ID: 10675071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.
    ; Dagenais GR; Gerstein HC; Holman R; Budaj A; Escalante A; Hedner T; Keltai M; Lonn E; McFarlane S; McQueen M; Teo K; Sheridan P; Bosch J; Pogue J; Yusuf S
    Diabetes Care; 2008 May; 31(5):1007-14. PubMed ID: 18268075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetes prevention between RAAS inhibition and PPAR-gamma stimulation: the diabetes reduction assessment with ramipril and rosiglitazone medication (DREAM) trial.
    McFarlane SI; Provilus A; Shin JJ
    J Cardiometab Syndr; 2007; 2(2):149-50. PubMed ID: 17684471
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.